Cue Biopharma (CUE) AI Stock Analysis

• Market Cap: $31.11M
• Dividend Yield: N/A
• Average Volume (3M): 238.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: -25.51%
• EPS Growth: 49.72%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 91,237,740
• 10 Day Avg. Volume: 365,762
• 30 Day Avg. Volume: 238,588
• PEG Ratio: 0.04
• Price to Book (P/B): 3.51
• Price to Sales (P/S): 6.61
• P/FCF Ratio: -1.69
• Enterprise Value/Market Cap: 1.46
• Enterprise Value/Revenue: 6.38
• Enterprise Value/Gross Profit: 6.45
• Enterprise Value/Ebitda: -1.28
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.37 ▲(7.94% Upside)

The score is primarily held down by weak financial performance (declining revenue and very large losses) and bearish technicals (below key moving averages with negative MACD). Corporate events modestly offset this by extending cash runway and adding partnership upside, while valuation remains unattractive/unclear due to negative earnings and no dividend.

Positive Factors

Proprietary biologics platform

Cue’s proprietary Cue Biologics/Immuno-STAT platform is a durable competitive asset, enabling targeted T‑cell modulation across indications. Platform-driven discovery supports multiple candidates, licensing and partnership economics, reducing dependency on a single asset and enhancing long-term upside.

Strategic ImmunoScape collaboration

The ImmunoScape partnership structurally extends Cue’s commercialization pathway by leveraging a partner’s cell therapy expertise while providing durable non-cash economics (equity and royalties). This derisks internal development and aligns long-term incentives without immediate large capex demands.

High gross profit margin

A sustained gross margin near 99% indicates attractive unit economics typical of biologics, implying strong potential profitability on product sales or licensing. Once commercialized, high gross margins can support reinvestment, partnerships and favorable royalty negotiations over the long term.

Negative Factors

Declining revenue and large losses

Persistent revenue declines and deep negative margins signal structural profitability challenges. Large losses erode equity and limit internal funding capacity for trials and R&D, increasing reliance on external financing and dilutive transactions that can constrain long-term strategic flexibility.

Strained cash flow coverage

Negative operating cash flow and marginal free cash flow coverage mean the business cannot sustainably self‑fund development. This structural cash shortfall forces repeated financing, weakens negotiating leverage with partners, and raises the risk of program delays or curtailed R&D investment.

Chief Medical Officer departure

Loss of the CMO is a material operational risk for a clinical‑stage biotech: it can disrupt trial oversight, regulatory interactions and program continuity. Recruiting comparable clinical leadership can take months, potentially delaying development timelines and impacting partner confidence.

Cue Biopharma Business Overview & Revenue Model

Company Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at harnessing the body's immune system to fight cancer and autoimmune diseases. The company operates primarily in the biopharmaceutical sector, specializing in its proprietary Cue Biologics platform, which enables the design of biologics to selectively modulate immune responses. Cue Biopharma's core products include immune modulators that target specific T cell populations, with several candidates currently in clinical trials for various indications.

How the Company Makes Money

Cue Biopharma generates revenue through a combination of clinical trial partnerships, research collaborations, and potential milestone payments from its pharmaceutical partners. The company often enters into partnerships with larger pharmaceutical firms, which provide funding for the development of its drug candidates in exchange for rights to commercialize the products. Additionally, Cue Biopharma may receive royalties on future sales of successful therapies. The company's revenue model is heavily reliant on the success of its clinical trials, as positive results can lead to increased interest from potential partners and investors.

Cue Biopharma Financial Statement Overview

Summary

Cue Biopharma is facing significant financial challenges, characterized by persistent losses and negative cash flows. While there is some revenue growth, the company's profitability and cash generation remain under pressure. The balance sheet shows moderate leverage, but the negative return on equity and ongoing cash burn pose risks to financial stability.

Income Statement

Cue Biopharma's income statement reveals significant challenges in profitability, with negative net profit margins and EBIT margins over the TTM period. Although there is a slight revenue growth, the company struggles with high operating losses, indicating inefficiencies in cost management. The gross profit margin is relatively high, suggesting potential for improvement if operational costs are controlled.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. However, the negative return on equity highlights the company's inability to generate profits from shareholders' investments. The equity ratio is stable, but the overall financial health is weakened by consistent losses.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow, reflecting ongoing cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that cash outflows are closely aligned with net losses. The company faces challenges in generating positive cash flows, which could impact its liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.10M	9.29M	5.49M	1.25M	14.94M	3.15M
Gross Profit	7.02M	9.29M	-32.61M	1.25M	16.72M	-30.39M
EBITDA	-35.43M	-37.53M	-46.05M	-50.49M	-45.44M	-43.99M
Net Income	-37.68M	-40.67M	-50.73M	-53.01M	-44.16M	-44.78M
Balance Sheet
Total Assets	31.64M	32.19M	61.53M	91.28M	83.40M	99.53M
Cash, Cash Equivalents and Short-Term Investments	18.67M	23.39M	48.51M	76.29M	64.37M	84.87M
Total Debt	6.17M	8.88M	14.70M	19.32M	12.02M	7.15M
Total Liabilities	18.40M	14.69M	24.45M	25.60M	17.91M	20.62M
Stockholders Equity	13.25M	17.50M	37.09M	65.68M	65.49M	78.91M
Cash Flow
Free Cash Flow	-29.82M	-36.40M	-39.96M	-41.98M	-39.75M	-33.09M
Operating Cash Flow	-29.64M	-36.33M	-39.96M	-41.81M	-38.84M	-32.49M
Investing Cash Flow	-6.95M	32.00K	25.00M	-24.61M	9.11M	4.46M
Financing Cash Flow	15.87M	10.24M	11.86M	53.66M	19.23M	58.61M

Cue Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.49, and below the 200-day MA of 0.69, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.95 is Neutral, neither overbought nor oversold. The STOCH value of 39.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUE.

Cue Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$57.75M	-0.86	-50.23%	―	―	21.17%
CELU	44 Neutral	$38.35M	-0.40	―	―	-15.81%	-113.06%
MAIA	44 Neutral	$61.10M	-2.22	-2691.06%	―	―	44.50%
CUE	42 Neutral	$31.11M	-0.75	-195.19%	―	-25.51%	49.72%
ALGS	42 Neutral	$55.69M	-0.46	-141.82%	―	-55.88%	6.14%

Cue Biopharma Corporate Events

Cue Biopharma Announces $10 Million Public Equity Offering

On December 19, 2025, Cue Biopharma priced an underwritten public offering of 35,714,286 shares of common stock, or pre-funded warrants in lieu of shares, together with accompanying common stock warrants to purchase 17,857,143 shares, at a combined price of $0.28 per share-and-warrant unit (or $0.279 for units with pre-funded warrants), for expected gross proceeds of about $10 million before fees and expenses. All securities in the deal are being sold by the company, with H.C. Wainwright & Co. acting as sole bookrunner and Newbridge Securities as co-manager, and the underwriters have been granted a 30-day option to purchase up to an additional 5,357,140 shares and/or 2,678,570 warrants; the offering, expected to close around December 22, 2025, is projected, together with existing cash, marketable securities and payments from its ImmunoScape collaboration, to fund Cue Biopharma’s operations into the first quarter of 2027, extending its cash runway and potentially alleviating near-term financing pressure for stakeholders despite the dilutive impact of the equity and warrant issuance.

The most recent analyst rating on (CUE) stock is a Sell with a $0.32 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Cue Biopharma Releases Updated Corporate Presentation

On November 24, 2025, Cue Biopharma, Inc. made an updated corporate presentation available on its website. This announcement does not affect the company’s filings under the Securities Exchange Act of 1934 or the Securities Act of 1933, unless specifically referenced.

The most recent analyst rating on (CUE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Cue Biopharma Announces CMO Departure

On November 17, 2025, Cue Biopharma, Inc. announced the termination of employment for its Chief Medical Officer, Dr. Matteo Levisetti, effective November 28, 2025. Dr. Levisetti will receive severance benefits, including a lump sum cash payment and continued health insurance coverage under COBRA, as part of his separation agreement.

The most recent analyst rating on (CUE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Cue Biopharma Partners with ImmunoScape for Cell Therapy

On November 6, 2025, Cue Biopharma and ImmunoScape announced a strategic collaboration to develop a novel cell therapy approach for solid tumors. This agreement allows ImmunoScape to research, develop, and commercialize molecules from Cue Biopharma’s CUE-100 Series, aiming to advance a ‘Seed-and-Boost’ immunotherapy approach. The collaboration is expected to enhance Cue Biopharma’s focus on autoimmune disease programs and advance its Immuno-STAT platform in oncology, potentially providing a breakthrough in T cell therapy with improved efficacy and tolerability. Cue Biopharma will receive significant financial benefits, including equity in ImmunoScape and royalties from future sales.

The most recent analyst rating on (CUE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.